Jarno E. J. Wolters

Jarno E. J. Wolters

Auto-generated profile, based on publicly available information

Jarno E. J. Wolters

Department of Toxicogenomics, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Current Opinion in Ophthalmology
Verified
Journal Article
Closed access
JWJarno E.J. Wolters
Jarno E.J. Wolters
RMRalph J.S. van Mechelen
Ralph J.S. van Mechelen
RMRana Al Majidi
Rana Al Majidi
LPLeonard Pinchuk
Leonard Pinchuk
CWCarroll A.B. Webers
Carroll A.B. Webers
TGtheo G.M.F. gorgels
theo G.M.F. gorgels
Purpose of review: Mitomycin C (MMC) is an alkylating agent with extraordinary ability to crosslink DNA, preventing DNA synthesis. By this virtue, MMC is an important antitumor drug. In addition, MMC has become the gold standard medication for glaucoma filtration surgery (GFS). This eye surgery creates a passage for drainage of aqueous humor (AqH) out of the eye into the sub-Tenon's space with the aim of lowering the intraocular pressure. A major cause of failure of this operation is fibrosis and scarring in the sub-Tenon's space, which will restrict AqH outflow. Intraoperative application of MMC during GFS has increased GFS success rate, presumably mainly by reducing fibrosis after GFS. However, still 10% of glaucoma surgeries fail within the first year. Recent findings: In this review, we evaluate risks and benefits of MMC as an adjuvant for GFS. In addition, we discuss possible improvements of its use by adjusting dose and method of administration. Summary: One way of improving GFS outcome is to prolong MMC delivery by using a drug delivery system.

9 July 2015 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
JJJian Jiang
Jian Jiang
JWJarno Ej Wolters
Jarno Ej Wolters
SBSimone G van Breda
Simone G van Breda
JKJos C Kleinjans
Jos C Kleinjans
TKTheo M de Kok
Theo M de Kok
Development of novel tools for the in vitro investigation of drug-induced liver injury. . ???aop.label???.

13 September 2017 in Chemical Research in Toxicology
Verified
Journal Article
Open access
JWJarno E. J. Wolters
Jarno E. J. Wolters
SBSimone G. J. van Breda
Simone G. J. van Breda
FCFlorian Caiment
Florian Caiment
SCSandra M. Claessen
Sandra M. Claessen
TKTheo M. C. M. de Kok
Theo M. C. M. de Kok
JKJos C. S. Kleinjans
Jos C. S. Kleinjans
Valproic acid (VPA) is one of the most widely prescribed antiepileptic drugs in the world. Despite its pharmacological importance, it may cause liver toxicity and steatosis through mitochondrial dysfunction. The aim of this study is to further investigate VPA-induced mechanisms of steatosis by analyzing changes in patterns of methylation in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, primary human hepatocytes (PHHs) were exposed to an incubation concentration of VPA that was shown to cause steatosis without inducing overt cytotoxicity. VPA was administered daily for 5 days, and this was followed by a 3 day washout (WO). Methylated DNA regions (DMRs) were identified by using the methylated DNA immunoprecipitation–sequencing (MeDIP-seq) method. The nDNA DMRs after VPA treatment could indeed be classified into oxidative stress- and steatosis-related pathways. In particular, networks of the steatosis-related gene EP300 provided novel insight into the mechanisms of toxicity induced by VPA treatment. Furthermore, we suggest that VPA induces a crosstalk between nDNA hypermethylation and mtDNA hypomethylation that plays a role in oxidative stress and steatosis development. Although most VPA-induced methylation patterns appeared reversible upon terminating VPA treatment, 31 nDNA DMRs (including 5 zinc finger protein genes) remained persistent after the WO period. Overall, we have shown that MeDIP-seq analysis is highly informative in disclosing novel mechanisms of VPA-induced toxicity in PHHs. Our results thus provide a prototype for the novel generation of interesting methylation biomarkers for repeated dose liver toxicity in vitro.

1 June 2018 in Toxicology Letters
Verified
Journal Article
Open access
JWJarno E.J. Wolters
Jarno E.J. Wolters
Simone Van BredaSimone Van Breda
Simone Van Breda
JGJonas Grossmann
Jonas Grossmann
CFClaudia Fortes
Claudia Fortes
FCFlorian Caiment
Florian Caiment
JKJos C.S. Kleinjans
Jos C.S. Kleinjans
We performed a multiple 'omics study by integrating data on epigenomic, transcriptomic, and proteomic perturbations associated with mitochondrial dysfunction in primary human hepatocytes caused by the liver toxicant valproic acid (VPA), to deeper understand downstream events following epigenetic alterations in the mitochondrial genome. Furthermore, we investigated persistence of cross-omics changes after terminating drug treatment. Upon transient methylation changes of mitochondrial genes during VPA-treatment, increasing complexities of gene-interaction networks across time were demonstrated, which normalized during washout. Furthermore, co-expression between genes and their corresponding proteins increased across time. Additionally, in relation to persistently decreased ATP production, we observed decreased expression of mitochondrial complex I and III-V genes. Persistent transcripts and proteins were related to citric acid cycle and β-oxidation. In particular, we identified a potential novel mitochondrial-nuclear signaling axis, MT-CO2-FN1-MYC-CPT1. In summary, this cross-omics study revealed dynamic responses of the mitochondrial epigenome to an impulse toxicant challenge resulting in persistent mitochondrial dysfunctioning. Moreover, this approach allowed for discriminating between the toxic effect of VPA and adaptation.

31 January 2022 in Experimental Eye Research
Verified
Journal Article
Open access
RMRalph J.S. van Mechelen
Ralph J.S. van Mechelen
JWJarno Ej. Wolters
Jarno Ej. Wolters
CBChristian J.F. Bertens
Christian J.F. Bertens
CWCarroll A.B. Webers
Carroll A.B. Webers
FBFrank J.H.M. van Den Biggelaar
Frank J.H.M. van Den Biggelaar
HBHenny J.M. Beckers
Henny J.M. Beckers
Glaucoma, a degenerative disease of the optic nerve, is the leading cause of irreversible blindness worldwide. Currently, there is no curative treatment. The only proven treatment is lowering intraocular pressure (IOP), the most important risk factor. Glaucoma filtration surgery (GFS) can effectively lower IOP. However, approximately 10% of all surgeries fail yearly due to excessive wound healing, leading to fibrosis. GFS animal models are commonly used for the development of novel treatment modalities. The aim of the present review was to provide an overview of available animal models and anti-fibrotic drug candidates. MEDLINE and Embase were systematically searched. Manuscripts until September 1st, 2021 were included. Studies that used animal models of GFS were included in this review. Additionally, the snowball method was used to identify other publications which had not been identified through the systematic search. Two hundred articles were included in this manuscript. Small rodents (e.g. mice and rats) are often used to study the fibrotic response after GFS and to test drug candidates. Due to their larger eyes, rabbits are better suited to develop medical devices. Novel drugs aim to inhibit specific pathways, e.g. through the use of modulators, monoclonal antibodies, aqueous suppressants or gene therapy. Although most newly studied drugs offer a higher safety profile compared to antimetabolites, their efficacy is in most cases lower when compared to MMC. Current literature on animal models and potential drug candidates for GFS were summarized in this review. Future research should focus on refining current animal models (for example through the induction of glaucoma prior to undertaking GFS) and standardizing animal research to ensure a higher reproducibility and reliability across different research groups. Lastly, novel therapies need to be further optimized, e.g. by conducting more research on the dosage, administration route, application frequency, the option of creating combination therapies, or the development of drug delivery systems for sustained release of anti-fibrotic medication.

2 December 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
JWJarno E. J. Wolters
Jarno E. J. Wolters
MHMarcel H. M. van Herwijnen
Marcel H. M. van Herwijnen
DTDaniel H. J. Theunissen
Daniel H. J. Theunissen
DJDanyel G. J. Jennen
Danyel G. J. Jennen
WHWim F. P. M. Van Den Hof
Wim F. P. M. Van Den Hof
JKJos C. S. Kleinjans
Jos C. S. Kleinjans